Multiple-variable dose regimen for treating tnfalpha-related disorders

A multiple-variable dose method for treating idiopathic inflammatory bowel disease in a subject in need thereof, comprising subcutaneously administering to the subject:

• a first dose of 160 mg of a recombinant human anti-TNFα antibody administered to the subject within a day;
• and
• a second dose of 80 mg of the antibody administered to the subject within a day, wherein the second dose is administered two weeks following administration of the first dose;
• wherein the antibody comprises:
• a heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:8;
• a CDR2 comprising the amino acid sequence of SEQ ID NO:6;
• and a CDR3 comprising the amino acid sequence of SEQ ID NO:4;
• and
• a light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:7;
• a CDR2 comprising the amino acid sequence of SEQ ID NO:5;
• and a CDR3 comprising the amino acid sequence of SEQ ID NO:3.

A multiple-variable dose method for treating idiopathic inflammatory bowel disease in a subject in need thereof, comprising subcutaneously administering to the subject:

• a first dose of 160 mg of a recombinant human anti-TNFα antibody administered as a set of four injections of 40 mg of the antibody administered to the subject within a day;
• and
• a second dose of 80 mg of the antibody administered as a set of two injections of 40 mg of the antibody administered to the subject within a day, wherein the second dose is administered two weeks following administration of the first dose;
• wherein the antibody comprises:
• a heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:8;
• a CDR2 comprising the amino acid sequence of SEQ ID NO:6;
• and a CDR3 comprising the amino acid sequence of SEQ ID NO:4;
• and
• a light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:7;
• a CDR2 comprising the amino acid sequence of SEQ ID NO:5;
• and a CDR3 comprising the amino acid sequence of SEQ ID NO:3.